NTRA News and Press, Natera Inc. From 04/23/24

2024-04-23 09:30:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2024, Baron Health Care Fund advanced 8.92% compared wi...

Demonstrates commitment to generating real-world clinical evidence to change disease management and improve patient outcomes Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the...

ProActive study shows Natera’s Prospera Kidney™ test detects rejection five months before biopsy Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting ...

Prospective, multi-center Trifecta-Heart and DTRT-2 studies demonstrate excellent performance of the Prospera Heart test for detecting rejection in adults and pediatrics Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of...

2024-04-05 18:30:02 ET Stephens analyst issues BUY recommendation for NTRA on April 5, 2024 05:00PM ET. The previous analyst recommendation was Buy. NTRA was trading at $96.75 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

2024-04-05 11:30:00 ET Summary There were 24 new analysts in March 2024. Gold, Bitcoin, a Bitcoin proxy pair trade, preferred shares, and a SOTP thesis are all covered. We lead off with some of the most discussed articles from last month, with a few that generated over 100 com...

Shares of Natera, Inc. (NASDAQ: NTRA) traded at a new 52-week high today and are currently trading at $95.17. So far today, approximately 361.85k shares have been exchanged, as compared to an average 30-day volume of 1.38M shares. Natera, Inc., a diagnostics company, develops and commercializ...

2024-04-05 10:00:07 ET Read the full article on Seeking Alpha For further details see: Natera upgraded at Bernstein on gross margin trajectory

Data demonstrates that MIBC patients who remain Signatera MRD-negative after surgery may be spared from adjuvant treatment, with 100% overall survival at 12 months Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 ...

2024-04-03 15:44:21 ET More on Natera Natera: Capitalizing On The Positive Momentum Of Personalized Medicine Natera, Inc. (NTRA) Q4 2023 Earnings Call Transcript Natera GAAP EPS of -$0.65 beats by $0.06, revenue of $311.1M beats by $23.78M Natera Q4 2023 Earn...